Reni Benjamin
Stock Analyst at Citizens
(1.36)
# 3,528
Out of 5,169 analysts
165
Total ratings
35.77%
Success rate
-13.57%
Average return
Main Sectors:
Stocks Rated by Reni Benjamin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMMP Immutep | Downgrades: Market Perform | n/a | $0.42 | - | 1 | Mar 13, 2026 | |
| IMMX Immix Biopharma | Initiates: Market Outperform | $23 | $9.46 | +143.13% | 1 | Mar 9, 2026 | |
| ALLO Allogene Therapeutics | Upgrades: Market Outperform | $5 | $2.15 | +132.56% | 9 | Jan 9, 2026 | |
| CMPX Compass Therapeutics | Initiates: Market Outperform | $10 | $5.32 | +87.97% | 1 | Dec 3, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Market Outperform | $10 → $12 | $4.70 | +155.32% | 15 | Oct 31, 2025 | |
| INBX Inhibrx Biosciences | Reiterates: Market Perform | n/a | $68.69 | - | 10 | May 15, 2025 | |
| CUE Cue Biopharma | Reiterates: Market Outperform | $2 | $0.26 | +656.43% | 5 | Apr 2, 2025 | |
| BCAB BioAtla | Maintains: Market Outperform | $5 → $1 | $0.16 | +525.00% | 9 | Mar 31, 2025 | |
| INCY Incyte | Reiterates: Market Perform | n/a | $92.24 | - | 28 | Mar 11, 2025 | |
| ACET Adicet Bio | Reiterates: Market Perform | n/a | $6.93 | - | 5 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $12 → $4 | $0.84 | +374.44% | 5 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $8 → $4 | $2.17 | +84.33% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.18 | - | 2 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $6.49 | - | 3 | Jun 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $10 | $14.87 | -32.75% | 2 | Oct 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $3 → $6 | $3.12 | +92.31% | 6 | Mar 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Outperform | $23 | $21.79 | +5.58% | 11 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $5 | $3.13 | +59.74% | 6 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $28 | $8.39 | +233.73% | 11 | Jun 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $8.33 | - | 2 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $40 | $15.60 | +156.41% | 4 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $3.77 | - | 11 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $8 | $9.97 | -19.76% | 1 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $60 | $42.83 | +40.09% | 1 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $8.99 | - | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $315 | $132.29 | +138.11% | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $76.66 | - | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $265 | $216.22 | +22.56% | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $28 → $17 | $3.76 | +352.13% | 3 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | n/a | $8.28 | - | 4 | Jun 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $2.98 | - | 2 | Feb 7, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $22 → $12 | $30.04 | -60.05% | 1 | Sep 25, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $18.48 | - | 1 | Nov 15, 2017 |
Immutep
Mar 13, 2026
Downgrades: Market Perform
Price Target: n/a
Current: $0.42
Upside: -
Immix Biopharma
Mar 9, 2026
Initiates: Market Outperform
Price Target: $23
Current: $9.46
Upside: +143.13%
Allogene Therapeutics
Jan 9, 2026
Upgrades: Market Outperform
Price Target: $5
Current: $2.15
Upside: +132.56%
Compass Therapeutics
Dec 3, 2025
Initiates: Market Outperform
Price Target: $10
Current: $5.32
Upside: +87.97%
Bicycle Therapeutics
Oct 31, 2025
Maintains: Market Outperform
Price Target: $10 → $12
Current: $4.70
Upside: +155.32%
Inhibrx Biosciences
May 15, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $68.69
Upside: -
Cue Biopharma
Apr 2, 2025
Reiterates: Market Outperform
Price Target: $2
Current: $0.26
Upside: +656.43%
BioAtla
Mar 31, 2025
Maintains: Market Outperform
Price Target: $5 → $1
Current: $0.16
Upside: +525.00%
Incyte
Mar 11, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $92.24
Upside: -
Adicet Bio
Mar 7, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $6.93
Upside: -
Jan 14, 2025
Maintains: Market Outperform
Price Target: $12 → $4
Current: $0.84
Upside: +374.44%
Aug 8, 2022
Maintains: Market Outperform
Price Target: $8 → $4
Current: $2.17
Upside: +84.33%
Dec 3, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $1.18
Upside: -
Jun 14, 2019
Reinstates: Market Perform
Price Target: n/a
Current: $6.49
Upside: -
Oct 12, 2018
Maintains: Outperform
Price Target: $11 → $10
Current: $14.87
Upside: -32.75%
Mar 11, 2026
Maintains: Market Outperform
Price Target: $3 → $6
Current: $3.12
Upside: +92.31%
Jan 20, 2026
Upgrades: Market Outperform
Price Target: $23
Current: $21.79
Upside: +5.58%
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $5
Current: $3.13
Upside: +59.74%
Jun 4, 2025
Reiterates: Market Outperform
Price Target: $28
Current: $8.39
Upside: +233.73%
Jun 2, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $8.33
Upside: -
Jun 2, 2025
Reiterates: Market Outperform
Price Target: $40
Current: $15.60
Upside: +156.41%
May 9, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $3.77
Upside: -
Mar 12, 2025
Maintains: Market Outperform
Price Target: $7 → $8
Current: $9.97
Upside: -19.76%
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $60
Current: $42.83
Upside: +40.09%
Feb 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $8.99
Upside: -
Feb 6, 2025
Reiterates: Market Outperform
Price Target: $315
Current: $132.29
Upside: +138.11%
Feb 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $76.66
Upside: -
Feb 6, 2025
Reiterates: Market Outperform
Price Target: $265
Current: $216.22
Upside: +22.56%
Nov 10, 2020
Downgrades: Outperform
Price Target: $28 → $17
Current: $3.76
Upside: +352.13%
Jun 14, 2019
Reinstates: Outperform
Price Target: n/a
Current: $8.28
Upside: -
Feb 7, 2019
Upgrades: Market Perform
Price Target: n/a
Current: $2.98
Upside: -
Sep 25, 2018
Downgrades: Outperform
Price Target: $22 → $12
Current: $30.04
Upside: -60.05%
Nov 15, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $18.48
Upside: -